Will Bausch + Lomb break free from debt-heavy Bausch Health? Sale rumours ignite market frenzy!

Will Bausch + Lomb break free from debt-heavy Bausch Health? Sale rumours ignite market frenzy!

Bausch + Lomb saw its stock surge by 13% in Toronto, trading at 24.01 Canadian dollars (around $17.67), following a report by the Financial Times suggesting the eye care company is considering a sale. The possible sale is being considered as a way to separate from its heavily indebted parent company, Bausch Health Companies Inc. […]

Valeant Pharmaceuticals to divest Sprout Pharmaceuticals in strategic move

Valeant Pharmaceuticals to divest Sprout Pharmaceuticals in strategic move

Valeant Pharmaceuticals International has announced a significant transaction involving the sale of Sprout Pharmaceuticals back to its original owners. This strategic divestiture includes a deal where Valeant will receive a 6% royalty on global sales of Sprout’s female libido drug, Addyi (flibanserin), for 18 months following the closure of the sale. Background of the Acquisition […]